This report evaluates the clinical validity and clinical utility of the Cologuard test (Exact Sciences Corp.).
PublicationsResearched and Curated by Clinical and Scientific Experts.
Every Hayes clinical evidence report is developed by experienced teams that have been trusted by healthcare decision makers since 1989. Here is a sampling of our content that is being used every day to inform defensible, evidence-based decisions by payers and providers.
Not all reports are available for public preview. For more information, please contact us.
Aortix Percutaneous Mechanical Circulatory Support Device
Aortix is a percutaneous mechanical circulatory support device for the treatment of chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure with worsening renal function.
Zavegepant (Zavzpret) for Acute Treatment of Migraine
Zavegepant is an intranasal novel small-molecule, calcitonin gene-related peptide (CGRP) receptor antagonist indicated for the acute treatment of migraine with or without aura in adults.
Omecamtiv Mecarbil for Heart Failure With Reduced Ejection Fraction (HFrEF)
Omecamtiv mecarbil is a first-in-class oral cardiac myosin activator under investigation for the treatment of heart failure with reduced ejection fraction (HFrEF).
Trofinetide (Daybue) for Rett Syndrome
Trofinetide (Daybue) is an oral synthetic glypromate analog indicated for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older.
Repetitive Transcranial Magnetic Stimulation for Treatment of Bipolar Disorder
Focus of the Report: The focus of this Health Technology Assessment is to evaluate the effectiveness and safety of repetitive transcranial magnetic stimulation (rTMS) for the treatment of adult patients with bipolar disorder (BD).
Technology Description: Transcranial magnetic stimulati…
Omaveloxolone (Skyclarys) for Friedreich Ataxia
Omaveloxolone is an oral drug that activates nuclear factor erythroid 2-related factor 2 (Nrf2). It is intended for treatment of Friedreich ataxia (FA), a rare hereditary neurodegenerative disorder that is driven by mitochondrial dysfunction and impaired Nrf2 activity. FA typically presents between the ages of 10 and 15 years.
ThyroSeq v3 Genomic Classifier (University of Pittsburgh Medical Center and Sonic Healthcare USA)
This report evaluates the clinical validity and clinical utility of the ThyroSeq v3 Genomic Classifier (University of Pittsburgh Medical Center and Sonic Healthcare USA).
MyoPro Orthosis (Myomo Inc.) for Upper Extremity Paralysis/Paresis After Stroke
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of the MyoPro orthosis (Myomo Inc.) for upper extremity paralysis/paresis after stroke to reduce motor impairment.
Delandistrogene Moxeparvovec for Duchenne Muscular Dystrophy
Delandistrogene moxeparvovec is a single-infusion gene therapy for the treatment of Duchenne muscular dystrophy.